Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Involvement of the Bufadienolides in the Detection and Therapy of the Acute Respiratory Distress Syndrome.

Abbas MMK, Patel B, Chen Q, Jiang W, Moorthy B, Barrios R, Puschett JB.

Lung. 2017 Jun;195(3):323-332. doi: 10.1007/s00408-017-9989-1. Epub 2017 Mar 4.

PMID:
28260175
2.

Comparison of Neurocognitive Testing and the Measurement of Marinobufagenin in Mild Traumatic Brain Injury: A Preliminary Report.

Oliver J, Abbas K, Lightfoot JT, Baskin K, Collins B, Wier D, Bramhall JP, Huang J, Puschett JB.

J Exp Neurosci. 2015 Jul 27;9:67-72. doi: 10.4137/JEN.S27921. eCollection 2015.

3.

Differing effects of resibufagenin on cinobufatalin- versus marinobufagenin-induced preeclampsia in a rodent model.

Puschett JB, Kumar B, Abbas MM.

Am J Perinatol. 2015 Jul;32(8):803-8. doi: 10.1055/s-0034-1396694. Epub 2014 Dec 29.

PMID:
25545447
4.

Marinobufagenin regulates permeability and gene expression of brain endothelial cells.

Ing NH, Berghman L, Abi-Ghanem D, Abbas K, Kaushik A, Riggs PK, Puschett JB.

Am J Physiol Regul Integr Comp Physiol. 2014 Jun 15;306(12):R918-24. doi: 10.1152/ajpregu.00499.2013. Epub 2014 Apr 9.

5.

Marinobufagenin predicts and resibufogenin prevents preeclampsia: a review of the evidence.

Puschett JB.

Am J Perinatol. 2012 Nov;29(10):777-85. doi: 10.1055/s-0032-1316447. Epub 2012 Jul 16. Review.

PMID:
22814872
6.

Marinobufagenin levels in preeclamptic patients: a preliminary report.

Agunanne E, Horvat D, Harrison R, Uddin MN, Jones R, Kuehl TJ, Ghanem DA, Berghman LR, Lai X, Li J, Romo D, Puschett JB.

Am J Perinatol. 2011 Aug;28(7):509-14. doi: 10.1055/s-0031-1272965. Epub 2011 Mar 4.

PMID:
21380994
7.

A chemifluorescent immunoassay for the determination of marinobufagenin in body fluids.

Abi-Ghanem D, Lai X, Berghman LR, Horvat D, Li J, Romo D, Uddin MN, Kamano Y, Nogawa T, Xu JP, Pettit GR, Puschett JB.

J Immunoassay Immunochem. 2011;32(1):31-46. doi: 10.1080/15321819.2010.538107.

PMID:
21253968
8.

Resibufogenin administration prevents oxidative stress in a rat model of human preeclampsia.

Uddin MN, Agunanne EE, Horvat D, Puschett JB.

Hypertens Pregnancy. 2012;31(1):70-8. doi: 10.3109/10641955.2010.525275. Epub 2010 Dec 21.

PMID:
21174582
9.

Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia.

Uddin MN, Horvat D, Demorrow S, Agunanne E, Puschett JB.

Biochim Biophys Acta. 2011 Jan;1812(1):49-58. doi: 10.1016/j.bbadis.2010.09.006. Epub 2010 Sep 17.

10.

Contribution of angiogenic factors in a rat model of pre-eclampsia.

Agunanne EE, Uddin MN, Horvat D, Puschett JB.

Am J Nephrol. 2010;32(4):332-9. doi: 10.1159/000319463. Epub 2010 Aug 19.

PMID:
20720407
11.

Genetic variation in solute carrier genes is associated with preeclampsia.

Morrison AC, Srinivas SK, Elovitz MA, Puschett JB.

Am J Obstet Gynecol. 2010 Nov;203(5):491.e1-491.e13. doi: 10.1016/j.ajog.2010.06.004. Epub 2010 Aug 5.

PMID:
20691413
12.

Emerging role of the bufadienolides in cardiovascular and kidney diseases.

Puschett JB, Agunanne E, Uddin MN.

Am J Kidney Dis. 2010 Aug;56(2):359-70. doi: 10.1053/j.ajkd.2010.01.023. Epub 2010 Apr 22. Review.

PMID:
20417001
13.

Marinobufagenin, resibufogenin and preeclampsia.

Puschett JB, Agunanne E, Uddin MN.

Biochim Biophys Acta. 2010 Dec;1802(12):1246-53. doi: 10.1016/j.bbadis.2010.02.005. Epub 2010 Feb 16.

14.

A 73-year-old-man with fever and weight loss.

Evans T, Cable C, Rappaport ES, Camarillo LC, Myers JD, Colbert CY, Mirkes CR, Puschett JB.

Am J Med Sci. 2010 Feb;339(2):164-8. doi: 10.1097/MAJ.0b013e3181c177d5. No abstract available.

PMID:
20019580
15.

Alterations in the renin-angiotensin system in a rat model of human preeclampsia.

Uddin MN, Agunanne E, Horvat D, Puschett JB.

Am J Nephrol. 2010;31(2):171-7. doi: 10.1159/000267099. Epub 2009 Dec 16.

PMID:
20016143
16.

Marinobufagenin causes endothelial cell monolayer hyperpermeability by altering apoptotic signaling.

Uddin MN, Horvat D, Childs EW, Puschett JB.

Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1726-34. doi: 10.1152/ajpregu.90963.2008. Epub 2009 Apr 22.

17.

Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome.

Horvat D, Severson J, Uddin MN, Mitchell B, Puschett JB.

Hypertens Pregnancy. 2010 Jan;29(1):1-9. doi: 10.3109/10641950802629709.

PMID:
19277924
18.

62-year-old-female with weakness and shortness of breath.

Henderson MH, Ogden PE, Sibbitt SJ, Colbert CY, Puschett JB, Scott RC 3rd.

Am J Med Sci. 2009 Feb;337(2):126-30. doi: 10.1097/MAJ.0b013e31818bb0bf. No abstract available.

PMID:
19214029
19.

Vascular leak in a rat model of preeclampsia.

Uddin MN, McLean LB, Hunter FA, Horvat D, Severson J, Tharakan B, Childs EW, Puschett JB.

Am J Nephrol. 2009;30(1):26-33. doi: 10.1159/000193220. Epub 2009 Feb 5.

20.

Vascular effects of the bufodienolides.

Puschett JB.

Trans Am Clin Climatol Assoc. 2008;119:103-12; discussion 112.

21.

Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function.

Uddin MN, Horvat D, Glaser SS, Mitchell BM, Puschett JB.

J Biol Chem. 2008 Jun 27;283(26):17946-53. doi: 10.1074/jbc.M800958200. Epub 2008 Apr 23.

22.

Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells.

Uddin MN, Horvat D, Glaser SS, Danchuk S, Mitchell BM, Sullivan DE, Morris CA, Puschett JB.

Placenta. 2008 Mar;29(3):266-73. doi: 10.1016/j.placenta.2007.12.009. Epub 2008 Feb 14.

PMID:
18279954
23.

Uncoupled endothelial nitric oxide synthase and oxidative stress in a rat model of pregnancy-induced hypertension.

Mitchell BM, Cook LG, Danchuk S, Puschett JB.

Am J Hypertens. 2007 Dec;20(12):1297-304.

PMID:
18047920
24.

Effects of resibufogenin in experimental hypertension.

Danchuk S, Sukhanov S, Horvat D, Uddin MN, Puschett JB.

Am J Nephrol. 2008;28(1):8-13. Epub 2007 Sep 20.

PMID:
17890853
25.

Marinobufagenin interferes with the function of the mineralocorticoid receptor.

Smith CL, He Q, Huang L, Foster E, Puschett JB.

Biochem Biophys Res Commun. 2007 May 18;356(4):930-4. Epub 2007 Mar 26.

26.

ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations.

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery/Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines.

J Vasc Interv Radiol. 2006 Sep;17(9):1383-97; quiz 1398. No abstract available.

PMID:
16990459
27.

Phenotypic characteristics shared by preeclamptic patients and an animal model of the syndrome: report of a pilot study.

Alper AB, Outland J, Finigan K, Pridjian G, Aina-Mumuney A, Puschett JB.

Am J Hypertens. 2006 Sep;19(9):947-50.

PMID:
16942938
28.

The role of excessive volume expansion in the pathogenesis of preeclampsia.

Puschett JB.

Med Hypotheses. 2006;67(5):1125-32. Epub 2006 Jul 11.

PMID:
16814939
29.

Beneficial effects of metolazone in a rat model of preeclampsia.

Pridjian G, Pridjian C, Danchuk S, Ianosi-Irimie M, Vu HV, Puschett JB.

J Pharmacol Exp Ther. 2006 Sep;318(3):1027-32. Epub 2006 May 22.

PMID:
16717105
30.

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation.

Circulation. 2006 Mar 21;113(11):e463-654. Review. No abstract available.

PMID:
16549646
31.

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation.

J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312. No abstract available.

32.

Marinobufagenin impairs first trimester cytotrophoblast differentiation.

LaMarca HL, Morris CA, Pettit GR, Nagowa T, Puschett JB.

Placenta. 2006 Sep-Oct;27(9-10):984-8. Epub 2006 Feb 2.

PMID:
16458353
33.

Resibufogenin corrects hypertension in a rat model of human preeclampsia.

Vu H, Ianosi-Irimie M, Danchuk S, Rabon E, Nogawa T, Kamano Y, Pettit GR, Wiese T, Puschett JB.

Exp Biol Med (Maywood). 2006 Feb;231(2):215-20.

PMID:
16446498
34.

A rat model of preeclampsia.

Ianosi-Irimie M, Vu HV, Whitbred JM, Pridjian CA, Nadig JD, Williams MY, Wrenn DC, Pridjian G, Puschett JB.

Clin Exp Hypertens. 2005 Nov;27(8):605-17.

PMID:
16303637
35.

Involvement of marinobufagenin in a rat model of human preeclampsia.

Vu HV, Ianosi-Irimie MR, Pridjian CA, Whitbred JM, Durst JM, Bagrov AY, Fedorova OV, Pridjian G, Puschett JB.

Am J Nephrol. 2005 Sep-Oct;25(5):520-8. Epub 2005 Sep 20.

PMID:
16179779
36.

Southern Society for Clinical Investigation Founders' Medal recipient's address.

Puschett JB.

Am J Med Sci. 2003 Dec;326(6):323-8. No abstract available.

PMID:
14671494
37.

Molecular effects of volume expansion on the renal sodium phosphate cotransporter.

Puschett JB, Whitbred J, Ianosi-Irimie M, Vu HV, Rabon E, Robinson J, Deininger P.

Am J Med Sci. 2003 Jul;326(1):1-8.

PMID:
12861119
38.

Preeclampsia. Part 2: experimental and genetic considerations.

Pridjian G, Puschett JB.

Obstet Gynecol Surv. 2002 Sep;57(9):619-40. Review.

PMID:
12218669
39.

Preeclampsia. Part 1: clinical and pathophysiologic considerations.

Pridjian G, Puschett JB.

Obstet Gynecol Surv. 2002 Sep;57(9):598-618. Review.

PMID:
12218668
40.

Diuretics and the therapy of hypertension.

Puschett JB.

Am J Med Sci. 2000 Jan;319(1):1-9. Review. No abstract available.

PMID:
10653440
41.

Phosphate transport inhibition by KW-3902, an adenosine A1 receptor antagonist, is mediated by cyclic adenosine monophosphate.

Cai H, Puschett DB, Guan S, Batuman V, Puschett JB.

Am J Kidney Dis. 1995 Nov;26(5):825-30.

PMID:
7485140
42.

Effect of myeloma light chains on phosphate and glucose transport in renal proximal tubule cells.

Batuman V, Guan S, O'Donovan R, Puschett JB.

Ren Physiol Biochem. 1994 Nov-Dec;17(6):294-300.

PMID:
7533308
44.

Pharmacological classification and renal actions of diuretics.

Puschett JB.

Cardiology. 1994;84 Suppl 2:4-13. Review.

PMID:
7954544
45.

Life-threatening hyperkalemia associated with captopril administration.

Doman K, Perlmutter JA, Muhammedi M, Puschett JB.

South Med J. 1993 Nov;86(11):1269-72.

PMID:
8235783
46.

Parathyroid hormone transport effects and hormonal processing in primary cultured rat proximal tubular cells.

O'Donovan RM, Widnell CC, Chen TC, Puschett JB.

Biochem J. 1993 Jul 15;293 ( Pt 2):377-80.

47.

Relationship of the renin-angiotensin system and systemic arterial pressure to sodium excretion during atrial natriuretic peptide infusion in men.

Grandis DJ, Uretsky BF, Verbalis JG, Chong TK, Puschett JB.

Am J Hypertens. 1992 Nov;5(11):793-9.

PMID:
1457079
48.

Diuretics in the therapy of hypertension: current status.

O'Donovan RA, Muhammedi M, Puschett JB.

Am J Med Sci. 1992 Nov;304(5):312-8. Review.

PMID:
1442873
49.

Iatrogenic hypercalcemia in hemodialysis patients.

Muhammedi MA, Piraino B, Rault R, Johnston JR, Puschett JB.

Clin Nephrol. 1991 Nov;36(5):258-61.

PMID:
1752077
50.

Indicator characteristics of bromothymol blue derivatives.

Puschett JB, Rao BS, Karandikar BM, Matyjaszewski K.

Talanta. 1991 Mar;38(3):335-8.

PMID:
18965151

Supplemental Content

Loading ...
Support Center